TL;DR
This paper introduces a novel multivariate method, Ensemble Sensitivity (ES), for identifying biomarkers in complex diseases like breast cancer. ES outperforms traditional univariate methods by capturing subtle biological signals missed by t-score based approaches, leading to improved classification accuracy and a more comprehensive set of identified biomarkers.
What Problem Does This Paper Address?
Identifying reliable biomarkers for complex diseases is a significant challenge. Gene expression data, while abundant, is inherently noisy and complex. Genes function within intricate networks, meaning that a single gene's misregulation can have cascading effects, making it difficult to distinguish "driver" genes (causative) from "passenger" genes (correlated). Furthermore, biological variability between patients and even within samples adds to the noise. Traditional methods often rely on univariate statistical scores (like the t-score) to rank genes, but these can miss important biomarkers that aren't significantly differentially expressed on their own but play crucial roles in network interactions or are affected by subtle, multivariate patterns. This paper aims to address this by proposing a more robust, multivariate approach to biomarker discovery.
Methods
The core contribution of this paper is the Ensemble Sensitivity (ES) algorithm. Unlike univariate methods that assess each gene's importance in isolation, ES employs a multivariate, supervised machine learning approach. Here's how it works:
- Ensemble Creation: A set of candidate features (genes or pathways) is first identified.
- Initial Importance Scoring: A supervised classifier is trained on this ensemble, and each feature is assigned an "importance score" based on its contribution to the classifier's performance.
- Sensitivity Analysis: The key innovation is the "sensitivity" step. For each feature, it's temporarily removed from the ensemble (with replacement), and the impact on the importance scores of the remaining features is measured.
- Average Change Calculation: The average change in importance scores across all such perturbations is calculated for each feature. Features whose importance scores consistently increase when other features are removed are considered biologically relevant and important.
- Biomarker Selection: Features with the largest average changes are selected for downstream analysis.
This ES algorithm is then integrated with the Core Module Biomarker Identification with Network Exploration (COMBINER) tool. COMBINER uses this ranked list of features to identify "core modules" (reproducible groups of pathway-associated genes) that best represent the disease phenotype. It then uses these modules to train and validate predictive classifiers.
Datasets
The study utilizes publicly available breast cancer gene expression datasets from three different cohorts:
- Netherlands: Van De Vijver et al. [2002]
- United States (USA): Wang et al. [2005]
- Belgium: Desmedt et al. [2007]
These datasets were combined, and only genes common to all three were used for analysis. Missing data was imputed using a k-nearest neighbors approach. Pathway information was sourced from the MSigDB v4.0 Canonical Pathways subset.
Key Insights and Ideas
- Multivariate vs. Univariate: The paper strongly advocates for multivariate approaches over traditional univariate methods (like the t-score) for biomarker discovery in complex biological systems.
- "Passenger" Genes Matter: The ES algorithm's ability to identify biomarkers that have relatively lower t-scores suggests it can capture the importance of "passenger" genes that mediate interactions within disease networks, even if they aren't directly differentially expressed.
- Complementary Signals: The minimal overlap between biomarkers identified by the ES algorithm and those identified by the t-score method highlights that these approaches capture different, complementary biological signals.
- Improved Predictive Power: By considering the collective impact of features, the ES algorithm leads to more robust biomarker sets that improve the accuracy of disease classification.
Key Results
- Improved Classification Accuracy: The ES algorithm, when used with COMBINER, improved the average Area Under the ROC Curve (AUC) by approximately 3% compared to the t-score ranking method across six inference/validation pairs of the breast cancer datasets.
- High Enrichment of Known Cancer Genes: For a threshold of 220 predicted biomarkers, the ES algorithm identified known cancer-related genes with approximately 93% overlap, representing a 3% improvement over the t-score method.
- Small Overlap Between Methods: The predicted biomarkers from the ES algorithm and the t-score method showed a small overlap, reinforcing the idea that they capture distinct biological information.
Limitations and Future Work
- Computational Complexity: The paper acknowledges that while the ES algorithm considers the removal of one feature at a time, extending this to removing multiple features simultaneously would improve accuracy but dramatically increase computational complexity.
- Greedy Approach in COMBINER: The COMBINER tool uses a greedy approach for finding the maximum AUC, meaning an optimal solution is not guaranteed.
- Future Directions: The authors suggest that further investigation into the biological function of the biomarkers identified by the ES algorithm is warranted. They also imply that exploring more sophisticated ensemble methods or feature removal strategies could further enhance performance.
Summary updated